Stefan Yee

chairman and non – executive director

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance.

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking and private equity with companies as KPMG, Linklaters, the Flemish investment bank Lessius, the Belgian Corporation for International Investment (SBI/BMI), Beluga (Euronext Brussels) and as the founder and CEO of the PE Group, a Belgian privately held private equity firm. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI, The Reference, Alro Holdings, Loomans Group, United Brands, Capco, Faseas International (Spacewell), HD Partners (Dekabo group), AED Rent, UnifiedPost Group, NRG New Generation, Axiles Bionics, including several healthcare companies (Docpharma (formerly Euronext Brussels), Uteron Pharma and Imcyse). Stefan holds Masters degrees in Law and Business Management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago (as a BAEF Fellow).

Leon Van Rompay

non – executive director

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in.

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee.

Marc Foidart

independent director

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL.

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL, Member of the Executive Committee of Noshaq SA in charge of the Life Sciences sector, CEO of B2H SA, the public company superseding the Liege life sciences ecosystem, and Investment Manager of Epimede SA, a EUR 50 million Belgian based private high-tech growth fund. He has more than 15 years of experience in strategic consulting and investment at all stages of development of small and medium high tech- high growth life sciences enterprises. He played a key role in several financing rounds at critical development stages of various Belgian young biotech companies among which: Mithra Pharmaceuticals SA, Imcyse SA, Uteron Pharma SA, PDC Line Pharma SA, Diagenode SA. As an entrepreneur, Marc Foidart is Co-Founder and past CEO of Arlenda SA, a spin-off company of the University of Liège providing expert statistical solutions to the pharmaceutical, chemical and environment industries. He is also Co-Founder and Executive Chairman of Eyed Pharma SA, a start-up company developing innovative controlled release microimplants in ophthalmology. Marc Foidart has been associate professor at the University of Liege since 2011.

Carolyn Myers

independent director

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care.

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care businesses. She is currently Principal of Bioensemble Ltd, a business strategy consulting firm that advises C-suite executives of small and medium size companies on a comprehensive range of drug development, commercial and business development services. Carolyn’s experience comes from having led many businesses in their growth strategies. At Allergan (formerly Actavis), she was the Vice President of Global Business Development and Alliance Management with a focus on expanding product portfolios. At Forest Laboratories (acquired by Actavis), Carolyn was the Vice President of the CNS marketing group responsible for marketing and sales of established and new products. At Mylan she held two different leadership positions including

President of Mylan Technologies, a division focused on developing generic transdermal systems and President of Dey Laboratories having full P&L responsibility to develop, manufacture and sell innovative respiratory products. Carolyn is also an advisor to several start-up organizations and capital investors.

Carolyn earned a PhD in Genetics from the University of British Columbia and an MBA from Rutgers University.

James Gale

independent director

James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 30 years of healthcare investing and finance experience.

Jim is a Managing Director in Signet Fund IV and is currently the Chairman of the Board of Alpex Pharma S.A., Knight Therapeutics Inc. (TSX: GUD), Teligent (NSDQ: TLGT, formerly IGI Laboratories), and also serves on the Board of Directors of Bionpharma, Chr. Olesen Synthesis A/S, CoreRx, LeonNanodrugs GmbH, Pharmaceutics International (Pii), Advantice Health, and RK Pharma. Prior portfolio company boards include Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., and Valera Pharmaceuticals.

Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Chris Buyse

Independent Director

Chris Buyse has more than 30 years of international expertise across the healthcare sector.

Chris is currently Managing Director of Fund+, the largest Belgian life sciences-dedicated venture capital fund and serves as member of the board of directors of several European companies listed on Nasdaq and Euronext, including iTeos Therapeutics, Celyad and Inventiva Pharma. Chris is also a Director of the Francqui Foundation, among other private mandates. Chris holds a Master’s Degree in applied economic sciences from the University of Antwerp, and an MBA from the Vlerick School of Management in Ghent.

Stijn Van Rompay

chief executive officer & co-founder

Mr. Stijn Van Rompay has over 20 years of experience in leadership positions at various pharmaceutical companies.

Stijn co-founded and was the CEO of Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen

chief business development officer & co-founder

Mr. Thomas Jacobsen has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development.

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.

Jean-Luc Vandebroek

Chief Financial Officer

Jean-Luc Vandebroek is a seasoned executive who joined us in September 2021 from his role as CFO of Bone Therapeutics, a publicly traded biotech company based in Gosselies, Belgium. Prior to that, he was CFO and CIO at Alcopa and Fluxys, and before that, he held various senior financial positions at Delhaize Group. Jean-Luc is an experienced Executive Board member and has a track record of developing and implementing financing strategies and transactions and has a large, global network of investors and financial institutions. Jean-Luc holds a Master in Business Administration from the Louvain Management School.

Dietmar Aichhorn

chief operating officer

Dr. Dietmar Aichhorn, PhD, has over 20 years of experience in various scientific roles within the pharmaceutical industry.

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing all scientific affairs. Dietmar graduated as chemical engineer in Linz but has perfected his project management skills at the university of Vienna.

Koenraad Van der Elst

chief legal officer

Mr. Koenraad Van der Elst has more than 30 years of experience as an in-house and external legal and general counsellor for various listed companies.

Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.

In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.


Millions of people worldwide suffer from acute, recurring pain flares in the bladder.

Alenura™ aims to become the first drug specifically approved to relieve pain Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

The medical indication

Symptoms include pelvic pressure and burning discomfort, increased urinary frequency, impacting every aspect of daily life. Episodes of painful flares last hours or days: the direct impact of the indication is amplified by stress, fatigue and even depression.

In healthy bladders, the inner lining of the bladder wall prevents urine from penetrating and reaching sensitive nerve ends.

A weakened inner layer of the bladder exposes the underlying tissue (urothelium) to toxic components in urine, like potassium.


The condition is suffered by millions worldwide, with estimates for the U.S. market alone starting at 6 million people, the majority of which are women.



U.S. patients (Low estimate – high estimate)
Women (1) 3.5M – 8.6M
Men (2) 2.4M – 5.3M
Total 5.9M – 13.9M

(1) RAND Study: J Urol. 2011 August, 186(2): 540–544. doi:10.1016/j.juro.2011.03.132

(2) RICE Study: J Urol. 2013 January, 189(1): 141–145. doi:10.1016/j.juro.2012.08.088

Annually, 3 million instillations of unapproved, compounded drug products take place in the US. Physicians are reimbursed for the instillation procedure but not for off label use of unapproved instillation products.

Our solution

No standardized treatment protocol for IC/BPS exists. Alenura™ aims to become the first product specifically approved for IC/BPS.

Current treatment protocols vary and have clear limitations. Alenura™ could become the first drug specifically approved to relieve pain Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), bringing reliable and standardized treatments to millions of patients.

Alenura™ aims to provide fast relief for acute painful symptoms, through a ready-to-use prefilled syringe for intra-vesicular administration through an instillation procedure.

Urologists recognize the unmet medical need and express an interest in Alenura™

We are developing a combination product of alkalinized lidocaine and heparin sodium, for which the mechanism of action is widely known thus reducing the risk for our drug development.

Alkalinized Lidocaine

  • Penetrates the bladder wall
  • Provides immediate pain relief
  • Helps reduce inflammation

Heparin Sodium

  • Augments the inner lining of the bladder (GAG layer)
  • Prevents further infiltration of toxic elements in urine
  • Anti-inflammatory & anti-microbial
  • Stabilizes alkalinized lidocaine

Alenura™ would be the only drug product that (1) treats pain acute flares and (2) regenerates the mucous layer of the bladder for prolonged pain relief.

Our commitment

The unique combination Alenura™ has already demonstrated efficient pain relief in controlled clinical trials, offering hope for patients in need.

In June of 2023 an ambitious phase 2 program was launched, including a 4-arm study comparing the efficacy of Alenura™ to its 2 components as well as placebo. The trial will enrol a target of 120 patients across multiple sites in the United States.

Hyloris has committed to staged investments of in total maximum USD 6.7 million. This stays within our financial goals of getting a product to market within 7 years and for less than €7 million on average.